Developer of a medical technology designed to analyse cell and genome engineering. The company's medical technology specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development of therapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research.
Year Founded
2011
Employees
50
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Caribou Biosciences News and Updates
2023 Year in Review: An Exciting Moment in CRISPR-Land
Genetic Engineering & Biotechnology News | December 4, 2023
Waterloo alumni named among Forbes 30 Under 30 | Waterloo News
University of Waterloo | November 30, 2023
CRISPR and Cas Genes Market scrutinized in the new analysis
WhaTech Technology and Markets News | November 29, 2023
Forbes honors '30 Under 30' in healthcare for '24
Becker's Hospital Review | November 28, 2023
Hemp Area Organic Gummies, Best Cbd Gummy Flavor
Nigerians in Diaspora Commission | November 25, 2023
Should Biotechnology Stock Caribou Biosciences Inc (CRBU) Be in Your Portfolio Friday?
InvestorsObserver | November 24, 2023